| Methods |
Four‐week randomised, double‐blind study |
| Participants |
Depressed outpatients
Age range: 24‐63 years
Exclusion criteria: not stated |
| Interventions |
Fluoxetine: 11 participants
Amitriptyline: 12 participants
Fluoxetine dose range: 60‐80 mg/day
Amitriptyline dose range: 150‐200 mg/day
Temazepam (10‐20 mg) was allowed for sleep |
| Outcomes |
Efficacy data not reported. Only dropout rate |
| Notes |
Funding: by industry |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
Randomised, no further information |
| Allocation concealment (selection bias) |
Unclear risk |
No information provided |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of participants and personnel (performance bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Blinding of outcome assessment (detection bias)
All outcomes |
Unclear risk |
Double blind, no further information |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Number and reason for dropouts reported, but not included in the analysis |
| Selective reporting (reporting bias) |
Unclear risk |
Endpoint scores reported with standard deviation. Adverse events not reported |
| Other bias |
High risk |
Quote: "we thank Lilly Industries Ltd for financial support and drug assays", this company produces fluoxetine |
